The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Corlopam     8-chloro-2-(4-hydroxyphenyl)- 4...

Synonyms: Carlacor, fenoldopam, Fenoldopamum, CHEMBL588, Carlacor (TN), ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of fenoldopam


Psychiatry related information on fenoldopam

  • Simultaneous bilateral infusion of various dose combinations of fenoldopam (2.5-10 micrograms) and quinpirole (5-20 micrograms) elicited dramatic increases in stereotyped behaviors relative to the effects produced by corresponding doses of each drug alone [6].
  • In nephrectomized rats, the blood pressure effects of fenoldopam (assessed as area under the infusion time-response curve) were more pronounced than in sham-operated controls [7].

High impact information on fenoldopam


Chemical compound and disease context of fenoldopam


Biological context of fenoldopam


Anatomical context of fenoldopam


Associations of fenoldopam with other chemical compounds


Gene context of fenoldopam

  • Reduction in the expression of caveolin-2 with antisense oligonucleotides attenuated the stimulatory effect of fenoldopam on cyclic adenosine monophosphate (cAMP) accumulation [23].
  • Inhibition with the PKA blocker H-89 (10 microM) abolished the effect of fenoldopam [24].
  • In kidney slices, inhibition of PKC (1 microM chelerythrine) or ERK1/2 (20 microM PD-098089) pathways did not prevent the fenoldopam-induced internalization [24].
  • Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog [25].
  • We suggest that the effect of fenoldopam on PRL and TSH is mainly at the hypothalamic level [26].

Analytical, diagnostic and therapeutic context of fenoldopam


  1. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. Carey, R.M., Stote, R.M., Dubb, J.W., Townsend, L.H., Rose, C.E., Kaiser, D.L. J. Clin. Invest. (1984) [Pubmed]
  2. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study. Hadengue, A., Moreau, R., Bacq, Y., Gaudin, C., Braillon, A., Lebrec, D. Hepatology (1991) [Pubmed]
  3. Arterial medial necrosis and hemorrhage induced in rats by intravenous infusion of fenoldopam mesylate, a dopaminergic vasodilator. Yuhas, E.M., Morgan, D.G., Arena, E., Kupp, R.P., Saunders, L.Z., Lewis, H.B. Am. J. Pathol. (1985) [Pubmed]
  4. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. Young, J.B., Leon, C.A., Pratt, C.M., Suarez, J.M., Aronoff, R.D., Roberts, R. J. Am. Coll. Cardiol. (1985) [Pubmed]
  5. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. White, W.B., Radford, M.J., Gonzalez, F.M., Weed, S.G., McCabe, E.J., Katz, A.M. J. Am. Coll. Cardiol. (1988) [Pubmed]
  6. Enhanced behavioral stereotypies elicited by intrastriatal injection D1 and D2 dopamine agonists in intact rats. Bordi, F., Meller, E. Brain Res. (1989) [Pubmed]
  7. Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Cavero, I., Thiry, C., Pratz, J., Lawson, K. Clinical and experimental hypertension. Part A, Theory and practice. (1987) [Pubmed]
  8. Differential regulation of renal phospholipase C isoforms by catecholamines. Yu, P.Y., Asico, L.D., Eisner, G.M., Jose, P.A. J. Clin. Invest. (1995) [Pubmed]
  9. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Chatziantoniou, C., Ruan, X., Arendshorst, W.J. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  10. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension. Ventura, H.O., Messerli, F.H., Frohlich, E.D., Kobrin, I., Oigman, W., Dunn, F.G., Carey, R.M. Circulation (1984) [Pubmed]
  11. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Elliott, W.J., Weber, R.R., Nelson, K.S., Oliner, C.M., Fumo, M.T., Gretler, D.D., McCray, G.R., Murphy, M.B. Circulation (1990) [Pubmed]
  12. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. White, W.B., Halley, S.E. Arch. Intern. Med. (1989) [Pubmed]
  13. N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit. Schultz, M.J., Baas, M.C., van der Sluijs, H.P., Stamkot, G.A., Smit, W. Current medicinal chemistry. (2006) [Pubmed]
  14. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Reisin, E., Huth, M.M., Nguyen, B.P., Weed, S.G., Gonzalez, F.M. Hypertension (1990) [Pubmed]
  15. Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam. Murphy, M.B., McCoy, C.E., Weber, R.R., Frederickson, E.D., Douglas, F.L., Goldberg, L.I. Circulation (1987) [Pubmed]
  16. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Lass, N.A., Glock, D., Goldberg, L.I. Circulation (1988) [Pubmed]
  17. Dopamine D1A receptor regulation of phospholipase C isoform. Yu, P.Y., Eisner, G.M., Yamaguchi, I., Mouradian, M.M., Felder, R.A., Jose, P.A. J. Biol. Chem. (1996) [Pubmed]
  18. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. Blanchett, D.G., Green, J.A., Nara, A., Pospisil, R., Jarvis, R.C., Kasmer, R.J., Boyle, D.A., Cyronak, M.J., Corder, C.N. Clin. Pharmacol. Ther. (1991) [Pubmed]
  19. Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats. McCoy, C.E., Douglas, F.L., Goldberg, L.I. Hypertension (1986) [Pubmed]
  20. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Elliott, W.J., Karnezis, T.A., Silverman, R.A., Geanon, J., Tripathi, R.C., Murphy, M.B. Clin. Pharmacol. Ther. (1991) [Pubmed]
  21. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Brogden, R.N., Markham, A. Drugs (1997) [Pubmed]
  22. Dopamine- and cAMP-regulated phosphoprotein (DARPP-32) and dopamine DA1 agonist-sensitive Na+,K+-ATPase in renal tubule cells. Meister, B., Fryckstedt, J., Schalling, M., Cortés, R., Hökfelt, T., Aperia, A., Hemmings, H.C., Nairn, A.C., Ehrlich, M., Greengard, P. Proc. Natl. Acad. Sci. U.S.A. (1989) [Pubmed]
  23. D1 dopamine receptor signaling involves caveolin-2 in HEK-293 cells. Yu, P., Yang, Z., Jones, J.E., Wang, Z., Owens, S.A., Mueller, S.C., Felder, R.A., Jose, P.A. Kidney Int. (2004) [Pubmed]
  24. Activation of dopamine D1-like receptors induces acute internalization of the renal Na+/phosphate cotransporter NaPi-IIa in mouse kidney and OK cells. Bacic, D., Capuano, P., Baum, M., Zhang, J., Stange, G., Biber, J., Kaissling, B., Moe, O.W., Wagner, C.A., Murer, H. Am. J. Physiol. Renal Physiol. (2005) [Pubmed]
  25. Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog. Clark, K.L., Hilditch, A., Robertson, M.J., Drew, G.M. J. Hypertens. (1991) [Pubmed]
  26. Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. Boesgaard, S., Hagen, C., Andersen, A.N., Eldrup, E., Lange, P. Clin. Endocrinol. (Oxf) (1989) [Pubmed]
  27. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Bakris, G.L., Lass, N.A., Glock, D. Kidney Int. (1999) [Pubmed]
  28. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study. Sehgal, C.M., Arger, P.H., Silver, A.C., Patton, J.A., Saunders, H.M., Bhattacharyya, A., Bell, C.P. Radiology. (2001) [Pubmed]
  29. Effects of short-term fenoldopam infusion on gastric mucosal blood flow in septic shock. Morelli, A., Rocco, M., Conti, G., Orecchioni, A., De Gaetano, A., Coluzzi, F., Vernaglione, E., Pelaia, P., Pietropaoli, P. Anesthesiology (2004) [Pubmed]
  30. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Morelli, A., Ricci, Z., Bellomo, R., Ronco, C., Rocco, M., Conti, G., De Gaetano, A., Picchini, U., Orecchioni, A., Portieri, M., Coluzzi, F., Porzi, P., Serio, P., Bruno, A., Pietropaoli, P. Crit. Care Med. (2005) [Pubmed]
  31. 5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle. Gretler, D.D., Jones, K.C., Murphy, M.B. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
WikiGenes - Universities